The Corneum

All issues

92 evidence reviews of skincare, wellness and longevity treatments, newest first.

  1. #093 · Insufficient Data · Oct 8, 2026Metformin: The $4 Longevity PillProven for preventing diabetes, untested for aging, and two exercise trials say it may blunt the muscle older adults need most.
  2. #092 · Insufficient Data · Oct 1, 2026Nature's Ozempic Is NeitherSeven completers, no control group, and a 75% sales spike.
  3. #091 · Insufficient Data · Sep 24, 2026CGMs: The Same Meal, TwiceTwo sensors on one arm disagree about half your worst foods. Your own response to an identical meal barely correlates with itself. And 15,828 patients already tested whether flattening the spike saves a heart.
  4. #090 · Marketing Hype · Sep 11, 2026Plasma Exchange: 2.6 Years, Gone by Session SixA $60,000 blood-cleaning protocol built on one trial with ten people per arm, in which the rejuvenation had already vanished before the last treatment.
  5. #089 · Insufficient Data · Sep 9, 2026L-Tyrosine: The 10-Gram Nootropic Sold by the Half-GramIt works at 4°C and 4,700 meters. At your desk it does nothing. And the study that says it shortens men's lives measured nobody taking it.
  6. #088 · Promising · Sep 7, 2026Denifanstat: The Acne Pill That Turns Off the OilThe first new oral acne mechanism in 40 years has one Phase 3, zero published pivotal data, and a hair question nobody is asking.
  7. #087 · Promising · Sep 4, 2026Zasocitinib: The $4 Billion Sotyktu UpgradeTwo pivotal trials, one head-to-head, zero published papers. What the most selective psoriasis pill ever built actually shows.
  8. #086 · Promising · Sep 2, 2026Masseter Botox: 5.24 Millimeters of Jawline, Zero for Your TMJThe FDA just accepted Botox's fifth aesthetic indication. Three Allergan trials, a five-millimeter jawline, half the ideal patients unsatisfied, and no controlled data past 12 months on the bone underneath.
  9. #085 · Marketing Hype · Aug 28, 2026Creatine: 721 for Muscle, Zero for SkinThe best-evidenced supplement in sports nutrition just got a beauty rebrand. The four studies underneath it were run by Nivea, applied to the skin, against untreated forearms.
  10. #084 · Insufficient Data · Aug 26, 2026The Leaderboard Nobody RandomizedAlpha-ketoglutarate topped a survey of 84 supplements. The mouse program built to referee claims like this has tested it twice and found nothing both times.
  11. #083 · Insufficient Data · Aug 24, 2026Liquid Gold, Sold by the GramBovine colostrum has real clinical data. It's about sweaty cyclists, a urine sugar ratio, and five times the dose in your scoop.
  12. #082 · Promising · Aug 21, 2026Beta-GlucanThe Comparison Nobody Ran
  13. #081 · Insufficient Data · Aug 19, 2026The Ovary Clock and the Five-Year PromiseA Columbia trial gave 50 women a weekly pill for 12 weeks and measured one hormone. Somewhere between the lab and the headline, that became "delay menopause by five years" — and a $64-a-month subscription.
  14. #080 · Promising · Aug 19, 2026The $35 Billion Press Release1,137 patients, zero hazard ratios, and the biggest single-day stock move in Moderna's history.
  15. #079 · Marketing Hype · Aug 17, 2026Microdosing OzempicThe longevity crowd took the best-evidenced drug of the decade and removed the dose the evidence was about.
  16. #078 · Insufficient Data · Aug 12, 2026Mouth Taping: Ten Studies, Zero JawlinesThe entire global evidence base is 233 patients and one randomized trial. Nobody has ever measured the thing everyone buys it for.
  17. #077 · Promising · Aug 10, 2026Tudriqev: Twice Rejected, Once ApprovedThe FDA turned down this melanoma therapy twice, then approved it on the same data — using its own, much smaller number.
  18. #076 · Marketing Hype · Aug 7, 2026Cortisol FaceA rare disease, a real hormone, and a supplement aisle the FTC already emptied once.
  19. #075 · Marketing Hype · Aug 5, 2026Astaxanthin: The 12% That Didn't Come BackThe mouse result behind "nine more years of life" just failed to replicate, in the same program that found it.
  20. #074 · Insufficient Data · Aug 3, 2026The Everything SprayHypochlorous acid has real evidence in wounds. For your face, the published trial count is zero.
  21. #073 · Marketing Hype · Jul 29, 2026Tanmaxxing: The Tan Is the InjuryA base tan is worth about SPF 3. The sunscreen scare rests on a regulatory threshold that was never a safety threshold. And the nasal spray is a peptide no agency has approved for anyone.
  22. #072 · Marketing Hype · Jul 27, 2026Beef TallowRendered Claims, Unrendered Evidence
  23. #071 · Insufficient Data · Jul 24, 2026SpermidineThe longevity molecule that skipped the clinic: ~10% more life for mice, a flat human trial, and a $76 bottle.
  24. #070 · Insufficient Data · Jul 22, 2026ErgothioneineThe longevity vitamin that forgot to run a trial.
  25. #069 · Insufficient Data · Jul 20, 2026The 90-Year-Old "New" Fatty AcidFatty15 says C15:0 is the first essential fatty acid discovered in over 90 years. The dolphins were real. The label was invented by the company that sells it.
  26. #068 · Promising · Jun 26, 2026Tech Neck, Meet the FDASKINVIVE just became the first injectable approved for neck lines. The treatment is real and modestly effective. The tech-neck story selling it is not.
  27. #067 · Insufficient Data · Jun 24, 2026Glutathione: The Glow That Doesn't Survive DigestionThe viral skin-whitening molecule: the pill barely absorbs, the lotion is modest, and the IV 'glow drip' has no efficacy data and a Stevens-Johnson paper trail.
  28. #066 · Insufficient Data · Jun 22, 2026The Calcium WhispererVitamin K2 moves a biomarker, a calcium score, and a lot of supplement units. It has never moved a single heart attack.
  29. #065 · Insufficient Data · Jun 19, 2026Glucosamine and the 25% ScareA viral post says your joint pill accelerates Alzheimer's. The study is real, single-center, and barely adjusted, while half a million people in the UK Biobank point the other way.
  30. #064 · Marketing Hype · Jun 17, 2026The Skeptics' Greatest HitHigh LDL, the elderly, and the 92% soundbite that isn't what it seems.
  31. #063 · Marketing Hype · Jun 15, 2026The 44% Solution That Isn'tA viral jet-lag protocol promised a precise cure. The 44% traces to no study, and the 3mg dose is ten times what he actually takes.
  32. #062 · Marketing Hype · Jun 12, 2026Two Kiwis a DayWhat the '+50% Skin Density' Study Actually Measured
  33. #061 · Promising · Jun 12, 2026Once-Weekly Growth Hormone for KidsThree new weekly drugs cut a child's injections from 365 a year to 52. The trials prove they match daily GH for one year — not that they grow kids better, and not that they're safe for the long haul.
  34. #060 · Marketing Hype · Jun 8, 2026Chlorine Dioxide: The Cancer Cure That's Registered as a PesticideAn industrial bleach with zero oncology trials, eight poison-control deaths, and a family of sellers in federal prison.
  35. #059 · Strong Evidence · Jun 5, 2026The New World ScrewwormWe eradicated this flesh-eating parasite in 1966 and held the line with a jungle fly factory for sixty years. Then the barrier slipped, and a Texas calf became the first U.S. case in six decades.
  36. #058 · Promising · Jun 5, 2026Vitamin D and DiabetesThree big trials each came up empty. Pooled, they show a real but modest signal — in prediabetes only, at blood levels almost nobody hits.
  37. #057 · Marketing Hype · Jun 3, 2026The 96% Cure That Isn'tAn ear needle for alpha-gal: one uncontrolled case series, co-authored by the technique's inventor, became a viral cure. The catch — the allergy already fades on its own.
  38. #056 · Marketing Hype · Jun 1, 2026Anktiva: The Cancer Drug Cosplaying as a Longevity BreakthroughAn FDA-approved bladder-cancer immunotherapy, a billionaire's 'most important longevity drug of the decade,' zero human aging trials, and a fresh FDA warning letter.
  39. #055 · Promising · May 29, 2026The Back Chain AdvantageYour kid's speed, injury risk, and athletic ceiling may come down to which muscles they load first. Here's how to tell — and what to do about it.
  40. #054 · Insufficient Data · May 29, 2026The Sinclair EightForty-one trials, one Tally Health byline, and zero randomized evidence that moving an epigenetic clock means a longer life.
  41. #053 · Insufficient Data · May 27, 2026Vitamin B1: The PMS Miracle Built From One FootnoteA single 80-woman trial reported a 35% dip in PMS symptoms. The internet rounded it up to 96%.
  42. #052 · Insufficient Data · May 25, 2026Klotho: The Longevity Protein With a Zero in the Human ColumnTwenty percent longer life in mice. Sharper memory in eighteen monkeys. Completed human trials: zero. Price of the gene therapy anyway: $25,000.
  43. #051 · Marketing Hype · May 24, 2026Magnesium: The Mineral That Allegedly Fixes EverythingThe internet's favorite supplement is real medicine for a few narrow problems and a marketing fantasy for the rest.
  44. #050 · Insufficient Data · May 23, 2026Taurine: The Energy-Drink Amino That Got a Longevity PromotionOne blockbuster mouse study, zero human longevity trials, and a 2025 rebuttal that quietly demoted it back to 'well-tolerated.'
  45. #049 · Marketing Hype · May 22, 2026Thermography: The Breast Scan That Misses Half the CancersMammography's real flaws are worth arguing about. Swapping it for an infrared camera the FDA has warned about five times isn't the argument.
  46. #048 · Promising · May 21, 2026Bemotrizinol: The 25-Year Overnight SensationThe FDA may finally bless the UV filter the rest of the world has used since the Clinton administration. But "proposed" isn't "approved," and it won't be on a shelf near you this summer.
  47. #047 · Strong Evidence · May 21, 2026Icotrokinra: The Pill That Acts Like a ShotThe first oral psoriasis drug to clear skin like an IL-23 biologic — just don't confuse "biologic-level" with "best-in-class."
  48. #046 · Strong Evidence · May 21, 2026Retatrutide: The 30% DrugEli Lilly's triple-agonist set a new weight-loss record across three Phase III trials — and surfaced a skin side effect the Phase 2 data never showed.
  49. #045 · Insufficient Data · May 11, 2026MOTS-c: The Exercise Mimetic That Outlived Its SponsorSixteen amino acids, one bankrupt biotech, and a Phase 1b that matched placebo.
  50. #044 · Insufficient Data · Apr 26, 2026The Frog's PharmacyA bacterium from a Japanese tree frog's gut eliminated 100% of tumors in mice. The internet lost its mind. The science is more complicated.
  51. #043 · Promising · Apr 20, 2026The Great UnbaldingNew York Magazine declared hair loss science at "a real inflection point." Two drugs nobody's heard of are the reason why.
  52. #042 · Promising · Apr 18, 2026The Anti-Trip That Rewires Your BrainUC Davis engineered the hallucinations out of LSD and kept the neuroplasticity. One compound is now in human trials. The rest live in mice.
  53. #041 · Promising · Apr 5, 2026Epigenetic ReprogrammingThree participants, one eye injection, and a researcher whose last breakthrough cost GlaxoSmithKline $720 million
  54. #040 · Promising · Apr 5, 2026The Collagen CollapseNew 2025 research reveals semaglutide and tirzepatide directly suppress collagen-producing stem cells, trigger oxidative damage, and deplete dermal estrogen. The skin aging isn't just from weight loss.
  55. #039 · Insufficient Data · Apr 4, 2026BPC-157: The Injury Repair PeptideParalyzed rats walked again. Severed tendons regrew. Then someone asked: has anyone tested this in humans?
  56. #038 · Promising · Apr 4, 2026When Tetracyclines Fail80% of patients get the rash. 40% fail first-line treatment. Zero trials compare what comes next.
  57. #037 · Promising · Mar 29, 2026New Hair Loss DrugsTwo genuinely novel mechanisms enter clinical trials — one with strong Phase 3 data, one with an elegant theory and a shaky dataset
  58. #036 · Insufficient Data · Mar 26, 2026The Tamarind Microplastic DetoxA lab study removed 91% of microplastics from water using chemically modified tamarind — social media turned it into a dietary cure
  59. #035 · Promising · Mar 25, 2026The Microbe That Builds MuscleA gut bacterium linked to 29% greater grip strength in older adults — and how inulin-rich foods might feed it
  60. #034 · Promising · Mar 25, 2026Sofwave: The Comfortable FaceliftSeven parallel ultrasound beams, seven FDA clearances, zero randomized controlled trials, and a celebrity marketing machine running ahead of the science
  61. #033 · Promising · Mar 24, 2026Topical Fatty Acids for Hair RegrowthA Cell Metabolism study finds monounsaturated fats regrow mouse hair in 20 days. Your scalp is not a mouse.
  62. #032 · Insufficient Data · Mar 23, 2026Nattokinase vs. Statins1,062 participants, a viral podcast clip, and a three-year gold-standard trial that says the opposite of what you've been told
  63. #031 · Promising · Mar 23, 2026Multimineral Supplements and Biological Aging958 older adults, five epigenetic clocks, and a 2.6-month slowdown that Nature Medicine says matters — but your body might not notice
  64. #030 · Promising · Mar 21, 2026Ejaculation Frequency and Prostate Cancer31,925 men, one self-reported question, and a headline that wrote itself
  65. #029 · Marketing Hype · Mar 20, 2026Bras and Breast SaggingAn unpublished French study, a wellness influencer, and the peer-reviewed evidence they both ignored
  66. #028 · Insufficient Data · Mar 20, 2026Psilocybin and LongevityOne mouse study, zero human aging trials, and a viral tweet that skipped the dosing math
  67. #027 · Insufficient Data · Mar 20, 2026Senolytics for Skin AgingZero human skin trials, one troubling tumor signal, and a supplement aisle full of sub-clinical doses marketed as the fountain of youth
  68. #026 · Promising · Mar 14, 2026Personalized Cancer VaccinesA dying dog, a tech entrepreneur, and the 157-patient trial that actually matters
  69. #025 · Promising · Mar 12, 2026Oral Collagen Peptides23 randomized controlled trials show skin improvements. Zero of them were independently funded.
  70. #024 · Insufficient Data · Mar 12, 2026Topical RapamycinOne 13-person trial, a $400/month cream, and a longevity community that skipped ahead of the evidence
  71. #023 · Insufficient Data · Mar 12, 2026Hyperbaric Oxygen Therapy and Aging: The Pressure Chamber Fountain of YouthOne Israeli lab, one 35-person study, and a clinic chain built on the claim that sitting in a pressurized tube reverses biological aging
  72. #022 · Insufficient Data · Mar 12, 2026Salmon DNA: The Molecular Identity CrisisA $285 million skincare trend built on injectable evidence — with zero human trials for the serums you're actually buying
  73. #021 · Promising · Mar 12, 2026Low-Level Laser Therapy for Hashimoto's ThyroiditisOne Brazilian research group, 43 patients, and a claim that near-infrared light can replace your thyroid medication
  74. #020 · Promising · Mar 5, 2026VIR-5500: The Stealth Immunotherapy82% biomarker response in a 58-patient trial sparked a $1.7 billion deal
  75. #019 · Insufficient Data · Mar 5, 2026Procyanidin C1: The Grape Seed Longevity PillZero human aging trials. One data integrity flag. A 150-year claim built entirely on mice.
  76. #018 · Insufficient Data · Mar 4, 2026Red Light Therapy and Arterial PlaqueOne rabbit study, zero human trials, and a viral thread that skipped the fine print
  77. #017 · Promising · Mar 2, 2026Urolithin A: The Muscle Molecule With a Longevity Marketing ProblemA gut metabolite with real clinical data for strength and immunity — and a $125/month price tag built on claims the evidence doesn't support yet.
  78. #016 · Promising · Feb 25, 2026Retatrutide: The Triple ThreatEli Lilly's triple-agonist delivers record-breaking weight loss and reverses fatty liver in early trials.
  79. #015 · Strong Evidence · Feb 25, 2026Adquey (Difamilast)Japan has used this drug for three years. The U.S. just caught up.
  80. #014 · Insufficient Data · Feb 25, 2026Antiparasitic Drugs for CancerIvermectin and mebendazole: the studies the advocates don't cite
  81. #013 · Insufficient Data · Feb 25, 2026Methylene Blue for SkinA 150-year-old dye with zero human skin trials
  82. #012 · Marketing Hype · Feb 25, 2026The Peptide CrackdownBPC-157 and TB-500: 544 studies, 1 human trial, 0 RCTs
  83. #011 · Strong Evidence · Feb 25, 2026Tranexamic Acid for MelasmaA blood-clotting drug that may be the best melasma treatment you've never heard of
  84. #010 · Insufficient Data · Feb 25, 2026NMN / NAD+ SupplementsThe longevity molecule caught between mouse data and FDA politics
  85. #009 · Insufficient Data · Feb 25, 2026At-Home RF & MicroneedlingFDA safety warnings, recalled devices, and what actually works
  86. #008 · Promising · Feb 25, 2026PT-141 / BremelanotideThe FDA-approved peptide that treats desire, not mechanics
  87. #007 · Promising · Feb 25, 2026Microbiome SkincareStrain-specific science vs. generic probiotic marketing
  88. #006 · Insufficient Data · Feb 25, 2026BakuchiolOne 44-person study built a billion-dollar retinol alternative
  89. #005 · Strong Evidence · Feb 25, 2026Ozempic FaceThe facial aging side effect of GLP-1 drugs nobody warned you about
  90. #003 · Promising · Feb 25, 2026GHK-Cu Copper PeptideThe peptide with 50 years of data and a regeneration mythology
  91. #002 · Promising · Feb 25, 2026Red Light TherapyNASA wound healing tech turned wellness trend
  92. #001 · Insufficient Data · Feb 25, 2026Topical ExosomesThe $500 facial ingredient with a molecular identity crisis